Health Law Breaking News: June 26, 2020
Novartis and a subsidiary have agreed to pay a combined $345 million in criminal and regulatory penalties for violating provisions of the Foreign Corrupt Practices Act (FCPA). The companies entered into separate deferred prosecution agreements arising from charges filed in the District of New Jersey. According to the company, Novartis Greece paid bribes to hospitals, clinics, and doctors to use the company’s products, and falsified company records to conceal these bribes.
U.S. Attorney for the District of New Jersey Craig Carpenito said that the deferred prosecution agreement “shows that there will be a heavy price paid by companies that violate our laws, whether at home or overseas.”
- Novartis AG and Subsidiaries to Pay $345 Million to Resolve Foreign Corrupt Practices Act Cases, Department of Justice, U.S. Attorney’s Office, District of New Jersey
- Novartis, Alcon Pay $347 Million to Settle Bribery Probes, The Wall Street Journal